Geriatric Pharmacy Specialty Recertification Literature Study: Module 1A-C (Cert # L219149)

ACPE Numbers: Various – see listing below
Pre-Sale Date: 03/17/2021
Content Release Date: 04/14/2021
Expiration Dates: 10/19/2021
Activity Type: Application-based
CE Credits: 15 hours (BPS and ACPE)
Activity Fee: $55 (ASHP member); $110 (non-member)

Accreditation for Pharmacists

The American Society of Health-System Pharmacists and American College of Clinical Pharmacy are accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Target Audience

These Literature Studies are designed to help board-certified pharmacists who are seeking recertification credit hours to maintain their Board of Pharmacy Specialties (BPS).

Activity Overview

The Literature Study Module is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 3 online home study activities (see table below). Each activity is designed to assess the learners’ ability to analyze and apply peer-selected contemporary articles to practice. 

Module 1A Hypothyroidism: This module focuses on the clinical practice guidelines and treatments for subclinical hypothyroidism in the elderly. 

Module 1BInfectious Diseases: This module focuses on infectious diseases in the elderly, specifically asymptomatic bacteriuria, community-acquired pneumonia, and influenza, and vaccination efficacy. 

Module 1CParkinson's Disease: This module focuses on treatment guidelines, efficacy of istradefylline for gait disorders, atypical antipsychotics, levodopa, and nonmotor symptoms therapies for Parkinson's Disease in the elderly. 

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this Literature Study, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice. 

These activities are part of the ASHP and ACCP professional development program for BCGP recertification approved by the BPS. 

Recertification Credit*

Board certified pharmacists are eligible to receive up to 15 hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Activity

ACPE Number

Credit Hours

*Assessment Pass Point

Geriatric Pharmacy Recertification Literature Study
Module 1A: Hypothyroidism

0204-9999-21-971-H01-P

5.00

76%

Geriatric Pharmacy Recertification Literature Study
Module 1B: Infectious Diseases

0204-9999-21-972-H01-P

5.50

78%

Geriatric Pharmacy Recertification Literature
Module 1C: Parkinson's Disease

0204-9999-21-973-H01-P

4.50 79%

 

Articles and Learning Objectives

Module 1A: Hypothyroidism
ACPE Number: 0204-9999-21-971-H01-P 

This module focuses on the clinical practice guidelines and treatments for subclinical hypothyroidism in the elderly. 

Bekkering GE, Agoritsas T, Lytvyn L et al. Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline. BMJ. 2019;365:I2006. 

Learning Objectives:

  • Describe the clinical practice guideline from the MAGIC group and The British Medical Journal for the management of subclinical hypothyroidism in adult and elderly patient.
  • Develop recommendations for the management of subclinical hypothyroidism in adult and elderly patients. 

Blum MR, Gencer B, Adam L et al. Impact of thyroid hormone therapy on atherosclerosis in the elderly with subclinical hypothyroidism: a randomized trial. J Clin Endocrinol Metab. 2018; 103(8):2988-97. 

Learning Objectives:

  • Describe the study of thyroid hormone therapy on atherosclerosis in the elderly with subclinical hypothyroidism.
  • Develop recommendations for the use of thyroid hormone therapy in patients with atherosclerosis and subclinical hypothyroidism. 

de Montmollin M, Feller M, Beglinger S et al. L-thyroxine therapy for older adults with subclinical hypothyroidism and hypothyroid symptoms. Secondary analysis of a randomized trial. Ann Intern Med. 2020; 172(11):706-16. 

Learning Objectives:

  • Describe the study of L-thyroxine for subclinical hypothyroidism and hypothyroid symptoms in older adults.
  • Develop recommendations for the use of L-thyroxine in older adults with subclinical hypothyroidism and hypothyroid symptoms. 

Mooijaart SP, DuPuy RS, Stott DS et al. Association between levothyroxine treatment and thyroid-related symptoms among adults aged 80 years and older with subclinical hypothyroidism. JAMA. 2019; 322(20):1977-86. 

Learning Objectives:

  • Describe the study of levothyroxine treatment for subclinical hypothyroidism in adults 80 years of age and older.
  • Develop recommendations for the use of levothyroxine in patients 80 years of age and older with subclinical hypothyroidism. 

Stott DJ, Rodondi N, Kearney PM et al. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med. 2017; 376(26):2534-44. 

Learning Objectives:

  • Describe the study of thyroid hormone therapy for subclinical hypothyroidism in older adults.
  • Develop recommendations for the use of thyroid hormone therapy in older adults with subclinical hypothyroidism. 

Stott DJ, Gussekloo J, Kearney PM et al. Study protocol; thyroid hormone replacement for untreated older adults with subclinical hypothyroidism - a randomised placebo controlled trisl (TRUST). BMC Endocrine Disorders. 2017; 17(6). DOI:https://doi.org/10.1186/s12902-017-0156-8. February 3, 2017. 

Learning Objectives:

  • Describe the study of thyroid hormone replacement for subclinical hypothyroidism in older adults.
  • Develop recommendations for the use of thyroid hormone replacement in older adults with subclinical hypothyroidism. 

Module 1B: Infectious Diseases
ACPE Number: 0204-9999-21-972-H01-P 

This module focuses on infectious diseases in the elderly, specifically asymptomatic bacteriuria, community-acquired pneumonia, and influenza, and vaccination efficacy. 

Andrew MK, Bowles SK, Pawelec G et al. Influenza vaccination in older adults: recent innovations and practical applications. Drugs & Aging. 2019; 36:29-37. 

Learning Objectives:

  • Describe the study of vaccinations for influenza in older adults.
  • Develop recommendations for the use of influenza vaccinations in older adults. 

Aspinall R, Olivier Lang P. Vaccination choices for older people, looking beyond age specific approaches. Expert Rev Vaccines. 2018; 17(1):23-30. 

Learning Objectives:

  • Describe vaccination choices for older adults.
  • Develop recommendations for vaccinations in older adult patients. 

Metlay JP, Waterer GW, Long AC et al. Diagnosis and treatment of adults with community-acquired pneumonia: an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America Executive Summary. Am J Respir Crit Care Med. 2019; 200(7):809-21. 

Learning Objectives:

  • Describe the clinical practice guideline from the American Thoracic Society and Infectious Diseases Society of America for the management of community-acquired pneumonia  in older adults.
  • Develop recommendations for the management of community-acquired pneumonia in older adults. 

Nicolle LE, Gupta K, Bradley SF et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2019; 68(10): e83-75. 

Learning Objectives:

  • Describe the clinical practice guideline from the Infectious Diseases Society of America for the management of asymptomatic bacteriuria in older adults.
  • Develop recommendations for the management of asymptomatic bacteriuria in older adults. 

Module 1C: Parkinson's Disease
ACPE Number: 0204-9999-21-973-H01-P 

This module focuses on treatment guidelines, efficacy of istradefylline for gait disorders, atypical antipsychotics, levodopa, and nonmotor symptoms therapies for Parkinson's Disease in the elderly. 

Grimes D, Fitzpatrick M, Gordon J et al. Canadian guideline for Parkinson disease. CMAJ. 2019; 191(36):E989-1004. 

Learning Objectives:

  • Describe the clinical practice guideline from Parkinson Canada for the management of Parkinson’s Disease in patients with this disease.
  • Develop recommendations for the management of Parkinson’s Disease in patients with this disease. 

Iijima M, Orimo S, Terashi H et al. Efficacy of istradefylline for gait disorders with freezing of gait in Parkinson's disease: a single-arm, open-label, prospective, multicenter study. Expert Opin Pharmaco. 2019; 20(11):1405-11. 

Learning Objectives:

  • Describe the study of istradefylline for gait disorders in Parkinson’s Disease patients.
  • Develop recommendations for the use of istradefylline in patients with Parkinson’s Disease. 

Seppi K, Chaudhuri KR, Coelho M et al. Update on treatments for nonmotor symptoms of Parkinson's Disease---an evidence-based medicine review. Movement Disorders. 2019; 34(2):180-98. 

Learning Objectives:

  • Describe the study on treatments for nonmotor symptoms of Parkinson’s Disease.
  • Develop recommendations for the treatments for nonmotor symptoms in Parkinson’s Disease patients. 

Verschuur CVM, Suwijn SR, Boel JA et al. Randomized delayed-start trial of levodopa in Parkinson's Disease. N Engl J Med. 2019; 380(4):315-24. 

Learning Objectives:

  • Describe the study of levodopa for Parkinson’s Disease in adult patients.
  • Develop recommendations for the use of levodopa in older patients with Parkinson’s Disease. 

Zhang H, Wang L, Fan Y et al. Atypical antipsychotics for Parkinson's disease psychosis: a systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2019; 15:2137-49. 

Learning Objectives:

  • Describe the study of atypical antipsychotics for Parkinson’s Disease psychosis in older adults.
  • Develop recommendations for the use of atypical antipsychotics in older adult patients with Parkinson’s Disease psychosis. 

Faculty

Full Faculty Bios

Emily Ambizas, Pharm.D., MPH, BCGP
Associate Clinical Professor
St. John's University, College of Pharmacy and Health Sciences
Queens, New York 

Danielle Fixen, Pharm.D., BCGP, BCPS
Assistant Professor, Department of Clinical Pharmacy
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Aurora, Colorado 

Jamie McCarrell, Pharm.D., BCGP, BCPS, FASCP
Clinical Pharmacy Manager
BSA Health Systems
Amarillo, Texas 

Content Matter Experts

Amie Taggart Blaszczyk, Pharm.D., BCGP, BCPS, FASCP
Associate Professor of Geriatric Pharmacy Practice
Division Head of Geriatrics
Texas Tech University Health Sciences Center
School of Pharmacy
Dallas, Texas 

Dana G. Carroll, Pharm.D., BCGP, BCPS, CDE
Clinical Professor
Auburn University Harrison School of Pharmacy
University of Alabama Family Medicine
Auburn, Alabama 

Maria Shin, Pharm.D., BCGP, BCPS
Clinical Pharmacy Specialist in Internal Medicine
Robley Rex Louisville Veterans Affairs Medical Center
Louisville, Kentucky 

Reviewers

Holly L.Byrnes, Pharm.D., BCPS
Jill Sellers, Pharm.D, B.S.Pharm. 

Field Testers

Donna Adkins, Pharm.D., BCGP
Lisa Banks, Pharm.D., BCGP
Christopher Chilibeck, B.Sc.Pharm, CDE, BCGP
Sharon Clackum, Pharm.D., BCGP
Robin Cooke, B.S., Pharm.D., BCGP
Carolyn Dittmar, BSc.Phm., BCPS, ACPR
Ruth Emptage, Pharm.D., BCGP
Paula Evans, Pharm.D., M.S., BCGP
Michele Evink, BS, MS, Pharm.D., BCPS
Chris Fan-Lun, BScPhm, ACPR, BCGP
Cynthia Feucht, Pharm.D., BCPS, BCGP
Laura Finn, B.S., BCGP, FASCP
Nicole Folger, Pharm.D., BCGP
David Fox, Pharm.D. BCGP
Annapurna Gandikota, B.Pharm.
Dawn Gerber, Pharm.D., BCGP
Briana Graber, Pharm.D.
Laura Hanson, Pharm.D., BCGP
Joy Higa, Pharm.D., BCGP
Kathy Hitchens, Pharm.D., BCGP, MSBA
Shelly House, BScPharm, BCPS, CDE
Sandy Hrometz, B.S.Pharm., Ph.D., BCGP
Travis LaCore, Pharm.D., BCGP
Peter Lao, BCPS, BCOP, BCGP
Allen Lefkovitz, R.Ph., Pharm.D., BCGP, FASCP
Ward Lenart, Pharm.D.
Matthew Maddox, Pharm.D., BCGP, BCACP, CPH
Christine Martin, M.S., BCGP
Mark Mercure, B.Sc.Pharm. BCGP
Lee Meyer, Pharm.D., BCGP
Melissa Mitchell, Pharm.D., BCPS, BCPP, BCGP
Zoon PARK, Pharm.D., BCGP
Chris Paxos, Pharm.D., BCPP, BCPS, BCGP
Bridget Protus, Pharm.D., BCGP, CDP
Kellie  Quan, BCGP
Noorani Ramji, B.Sc.Pharm, ACPR, BCGP, CDE, APA
Shannon Robison, R.Ph., BCGP
Mahmoud Salem, BCGP
Lindsay Saum, Pharm.D., BCPS, BCGP
Elizabeth Sebranek Evans, Pharm.D., BCPS, BCGP
Diane Tin, BScPhm, CDE, BCGP
Erin Williams, Pharm.D., BCGP
Clifford Young, R.Ph., FCPhA, BCGP 

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP and ACCP are required that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content. 

All faculty and planners for ASHP and ACCP education activities are qualified and selected by ASHP and ACCP identify and are required to disclose any relevant financial relationships with commercial interests. ASHP and ACCP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

  • All planners, presenters, reviewers, ASHP and ACCP staff and others with an opportunity to control content report no financial relationships relevant to this activity. 

Methods and CE Requirements

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

  • Complete the attestation statement
  • Review all content
  • Complete and pass the assessments
  • Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

System Technical Requirements

Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites. 

View the minimum technical and system requirements for learning activities. 

Development

These activities were developed by ASHP and ACCP.